BIVI

BioVie Inc. (BIVI) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025 (Fiscal Q1 2026). BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurological disorders (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease. The company operates as a single segment and is currently pre-revenue.

Key Financial Metrics

Note: The company reported no debt principal outstanding as of September 30, 2025, having paid off notes payable in December 2024. Interest expense decreased significantly to $1,989.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by approximately $935,000 (22.5%) compared to the prior year quarter. This was driven by a $946,000 increase in Research and Development (R&D) expenses and a $216,000 increase in General and Administrative (G&A) expenses.
• R&D Expansion: R&D expenses rose to $2.9 million, primarily due to the launch of the Phase 2 Parkinson's Disease (Sunrise PD) study and the Long COVID clinical trial. Direct study costs increased by $1.2 million.
• Capital Raise: In August 2025, the company completed an underwritten public offering, raising net proceeds of approximately $10.5 million. This significantly improved liquidity, increasing cash balances by over $7.4 million during the quarter.
• Share Count: The weighted average shares outstanding increased significantly to 5.2 million (from 0.6 million in the prior year) due to the August 2025 offering and a 1:10 reverse stock split effected in July 2025.
• Grant Receivable: A grant receivable of $179,804 was recorded, down from $2.1 million in the prior quarter, reflecting the timing of reimbursements from the U.S. Department of Defense for the Long COVID program.

Outlook, Risks, and Management Commentary

• Clinical Pipeline:
  • Long COVID: The Phase 2 ADDRESS-LC study commenced in May 2025. The company received a $13.1 million grant from the DOD.
  • Parkinson's Disease: The Phase 2b Sunrise PD study commenced in April 2025.
  • Alzheimer's Disease: The Phase 3 trial was underpowered due to protocol violations at 15 sites. Management is considering adaptive trial features or a new Phase 3 design.
  • Liver Disease: Finalizing Phase 3 protocol for BIV201 (terlipressin) targeting a broader ascites population.
• Liquidity and Going Concern: Despite the recent capital raise, management states that the company has not generated revenue and future operations depend on securing additional financing. The filing explicitly states that these circumstances raise substantial doubt about the company's ability to continue as a going concern.
• Legal Proceedings: The company is defending against a consolidated securities class action lawsuit (denied motion to dismiss in March 2025) and three consolidated shareholder derivative lawsuits alleging breach of fiduciary duties related to the Alzheimer's trial data. The company believes claims are without merit.
• Dilution Risk: Significant dilution occurred via the August 2025 offering. Outstanding warrants increased to over 8.3 million shares, and the company has anti-dilution provisions on certain warrants that could further reduce exercise prices in future capital raises.

Investor Verification Checklist

• Cash Runway: Verify the projected burn rate against the $25 million cash balance to determine the timeline for the next capital raise.
• Legal Exposure: Monitor the status of the securities class action and derivative lawsuits, as discovery is ongoing and could result in significant costs or settlements.
• Alzheimer's Strategy: Confirm the specific path forward for the Alzheimer's program (adaptive enrollment vs. new trial) given the previous Phase 3 underpowering.
• Grant Reimbursement Timing: Track the receipt of the remaining DOD grant funds for the Long COVID study to ensure it offsets R&D spend as expected.
• Dilution Mechanics: Review the terms of the Acuitas warrants and the new public warrants to understand potential future dilution triggers.